Differentiated thyroid carcinoma: risk group assignment and management controversies.
In this review, we provide a framework for clinical decision-making in the treatment of differentiated thyroid cancer. The clinical discussion and treatment recommendations are relevant to an adult population (> 16 years of age). The natural history, pathogenesis, diagnostic tools, and treatment controversies in the management of this disease are explored. The roles of radioiodine therapy and thyroid-stimulating hormone (TSH) suppression and the treatment of locoregional disease are reviewed. This discussion provides a comprehensive assessment of management and treatment issues in differentiated thyroid cancer.
Fuchshuber
P
P
Department of Head and Neck, Roswell Park Cancer Institute, Buffalo, New York, USA.
Loree
T R
TR
DeLacure
M D
MD
Hicks
W L
WL
D000328:Adult; D000368:Aged; D003937:Diagnosis, Differential; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods; D018570:Risk Assessment; D015996:Survival Rate; D013959:Thyroid Diseases / Q000175:diagnosis; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000628:therapy; D016896:Treatment Outcome